Development of Novel Radiopharmaceuticals for SPECT and PET Imaging

This Reprint showcases a collection of peer-reviewed articles highlighting recent advances in the development, evaluation, and clinical translation of novel radiopharmaceuticals for SPECT and PET imaging. Reflecting the growing impact of Nuclear Medicine in precision healthcare, these contributions emphasize innovative molecular probes, emerging imaging targets, and theranostic strategies that integrate diagnosis and therapy to support personalized patient management. The included articles cover a broad spectrum of applications, including oncology, inflammation, infection, and metabolic disorders. Key topics include radiopharmaceuticals targeting immune checkpoint molecules, glioblastoma-associated targets, intracellular signaling pathways, tumor angiogenesis, and tumor hypoxia, as well as imaging approaches for inflammatory diseases. The collection also explores dual-modality PET/fluorescence probes, advances in radiochemistry and radiolabeling methodologies, optimization of tracer pharmacokinetics, and the practical challenges of the clinical implementation and regulatory approval of novel imaging agents. By bridging molecular design, target selection, multimodal imaging, and translational research, this volume covers current achievements, ongoing challenges, and future directions in radiopharmaceutical sciences, expanding the capabilities of SPECT and PET imaging. Combining original research and comprehensive analyses from experts in the field, this Reprint serves as an essential, up-to-date resource for researchers, clinicians, radiochemists, and healthcare professionals dedicated to molecular imaging and theranostics.